Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca's Zomig nasal spray has performed well in a large US study, demonstrating rapid onset of migraine relief with lasting effects, including headache response occurring as early as 15 minutes.
Subscribe to our email newsletter
In the study, Zomig nasal spray (zolmitriptan) provided significant migraine headache response and pain-free rates as early as 15 minutes post-dose in migraine sufferers, with significantly higher sustained headache response and pain-free rates at 24 hours compared with placebo.
Data also show that patients who used Zomig Nasal Spray were significantly more likely to be able to quickly return to normal activities compared with placebo.
Zomig nasal spray also demonstrated sustained duration of efficacy, with low rates of recurrence and need for additional medication. In patients treated with Zomig nasal spray who achieved headache response at two hours, there was no recurrence of moderate or severe pain or requirement for re-medication up to 24 hours post-dose in 52.6% of attacks, compared to 24.4% of attacks in placebo-treated patients who achieved headache response at two hours.
“Migraine pain can be physically disabling for many patients,” said Dr Ninan Mathew, director of Houston Headache Clinic, Houston. “Our study demonstrates that the fast onset of action of Zomig nasal spray helps patients whose lives are disrupted by their migraines return to normal activities in as little as 15 minutes in some cases.”
Zomig nasal spray was also well-tolerated in this study, with the majority of adverse events being transient and mild or moderate in intensity.